Results 131 to 140 of about 14,170 (209)

Crystallisation protocol for SARS-CoV-2 nsp3 macrodomain in P43 v2

open access: yes
The COVID-19 pandemic has demonstrated the need for novel therapeutic interventions and improved pandemic preparedness strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This protocol details an optimized crystallization method for the SARS-CoV-2 nsp3 macrodomain, a potential drug target. Using sitting drop vapor diffusion,
Jasmin Aschenbrenner   +4 more
openaire   +1 more source

J Virol Methods [PDF]

open access: yes
The current two-step VP7 and VP4 genotyping RT-PCR assays for rotaviruses have been linked consistently to genotyping failure in an estimated 30% of RVA positive samples worldwide.

core  

Crystallisation protocol for SARS-CoV-2 nsp3 macrodomain in P43 v1

open access: yes
The COVID-19 pandemic has demonstrated the need for novel therapeutic interventions and improved pandemic preparedness strategies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This protocol details an optimized crystallization method for the SARS-CoV-2 nsp3 macrodomain, a potential drug target. Using sitting drop vapor diffusion,
Jasmin Aschenbrenner   +4 more
openaire   +1 more source

Whole-genome characterisation of G12P[6] rotavirus strains possessing two distinct genotype constellations co-circulating in Blantyre, Malawi, 2008 [PDF]

open access: yes, 2017
Agbemabiese, CA   +10 more
core   +1 more source

The non-vesicular cholesterol transporter GRAMD1C is a pan-coronavirus antiviral target. [PDF]

open access: yesPLoS Biol
Su Z   +11 more
europepmc   +1 more source

Mem Inst Oswaldo Cruz [PDF]

open access: yes
BACKGROUNDAlthough first detected in animals, the rare rotavirus strain G10P[14] has been sporadically detected in humans in Slovenia, Thailand, United Kingdom and Australia among other countries.

core  

Home - About - Disclaimer - Privacy